FDG PET/CT in the detection of recurrent rectal cancer.

The purpose of this study was to assess the additional value of combined fluorine 18 (18F)-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in the follow-up of rectal cancer after surgery. Forty-eight examinations in 30 patients were evaluated retrospectively. CT and PET components were interpreted separately, and this was followed by a consensus reading. Sites of increased FDG uptake as well as PET/CT findings were categorized as benign (1), equivocal (2), or malignant (3). The standard of reference was histology or clinical and imaging follow-up for at least 6 months. Sensitivity, specificity, positive and negative predictive values, and accuracy for differentiating benign (14/31) from malignant (17/31) uptake sites in the small pelvis were 100%, 64%, 77%, 100%, and 84% for PET/CT, and 100%, 29%, 63%, 100%, and 68% for PET, respectively. Regarding extrapelvic abnormalities, PET/CT was able to distinguish benign (31/88) from malignant (57/88) with a sensitivity, specificity, positive and negative predictive values, and accuracy of 100%, 87%, 93%, 100%, and 95%, compared with 96%, 68%, 85%, 91%, and 86% for PET. The rare case of an FDG uptake of adrenal adenoma is documented. PET/CT is valuable in the staging of rectal cancer, particularly for excluding recurrent disease suspected by PET interpretation alone in a considerable number of patients.

Colliding / concomitant tumors of the intestine: report of 3 cases.

Collision/concomitant tumors of the intestine involving lymphomas are very rare. For these cases molecular genetic analyses are valuable diagnostic adjuncts. We report one collision tumor of the rectum (adenocarcinoma and peripheral T-cell lymphoma, unspecified), and two cases of concomitant tumors (carcinoma in the cecum and lymphoma in the ileum; carcinoma in the sigmoid and lymphoma in the ileum). The collision tumor (poorly differentiated adenocarcinoma and a peripheral T-cell lymphoma, unspecified) showed a variable proportion of the anaplastic tumor cells expressing lymphatic markers as well as cytokeratin. Only polymerase chain reaction (PCR) analysis revealing T-cell monoclonality of the anaplastic part of the colliding tumor allowed the correct diagnosis. In the second case, a moderately differentiated adenocarcinoma in the cecum with a concomitant B-cell Non-Hodgkin lymphoma in the ileum, PCR analysis was non contributory. In the third case (adenocarcinoma in the sigmoid colon and a follicular center lymphoma in the ileum) PCR analysis revealed gene rearrangement of the immunoglobulin heavy chain gene. We would like to emphasize that collision and concomitant tumors of the gut are rare and that molecular genetic analysis may be mandatory for correct diagnosis. It is our impression, that these tumors may be diagnosed more often in the intestinal tract if molecular genetic analysis and immunohistochemistry are used routinely, at least for all anaplastic tumors.